Further investigation into the interaction between these proteins downstream of ROS production, particularly SrcFK, ARHGEF1 and Rho-kinase, may inform the identification of new therapeutic targets for the treatment of cardiovascular diseases associated with oxidative stress, such as pulmonary hypertension. This evidence concerns the gene ARHGEF1 and pulmonary arterial hypertension.